1
|
Zhou D, Chu W, Chen H, Xu J. Exploration of Directing-Group-Assisted, Copper-Mediated Radiofluorination and Radiosynthesis of [ 18F]Olaparib. ACS Med Chem Lett 2024; 15:116-122. [PMID: 38229754 PMCID: PMC10788942 DOI: 10.1021/acsmedchemlett.3c00465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 12/08/2023] [Accepted: 12/13/2023] [Indexed: 01/18/2024] Open
Abstract
Copper-mediated radiofluorination (CMRF) of organoboronic precursors is the method of choice for late-stage radiofluorination of aromatic compounds as positron emission tomography (PET) radiotracers. However, CMRF generally requires harsh reaction conditions, a large amount of substrates, and harsh solvents (e.g., DMA) to proceed, affording variable radiochemical yields (RCYs). Using [18F]tosyl fluoride as the source of [18F]fluoride, we have found a highly efficient CMRF of organoboronic precursors, assisted by a directing group (DG) at the ortho position. The reaction can be carried out under mild conditions (even at room temperature) in acetonitrile and results in high RCYs, providing a novel strategy for the radiofluorination of aromatic compounds. The exploration of this strategy also provided more information about side reactions in CMRF. Using this strategy, [18F]olaparib has been radiosynthesized in high RCYs, with high molar activity and high chemical and radiochemical purities, demonstrating the great potential of DG-assisted CMRF in the preparation of 18F-labeled PET radiotracers.
Collapse
Affiliation(s)
- Dong Zhou
- Department of Radiology, School of
Medicine, Washington University in Saint
Louis, Saint Louis, Missouri 63110, United States
| | - Wenhua Chu
- Department of Radiology, School of
Medicine, Washington University in Saint
Louis, Saint Louis, Missouri 63110, United States
| | - Huaping Chen
- Department of Radiology, School of
Medicine, Washington University in Saint
Louis, Saint Louis, Missouri 63110, United States
| | - Jinbin Xu
- Department of Radiology, School of
Medicine, Washington University in Saint
Louis, Saint Louis, Missouri 63110, United States
| |
Collapse
|
2
|
Abstract
Glycogen synthase kinase 3 (GSK-3) is an enzyme that is dysregulated in oncology neurodegeneration, neuroinflammation and several mental health illnesses. As such, GSK-3 is a long-sought after target for positron emission tomography (PET) imaging and therapeutic intervention. Herein, we report on the development and radiofluorination of two oxazole-4-carboxamides, including one bearing a non-activated aromatic ring. Both compounds demonstrated excellent selectivity in a kinase screen and inhibit GSK-3 with high affinity. [18F]OCM-49 was synthesized from [18F]fluoride using a copper-mediated reaction of an aryl boronic acid precursor, while [18F]OCM-50 used a trimethylammonium triflate precursor, and both radiotracers were translated for preclinical PET imaging in rodents. Due to superior radiochemical yields and brain uptake (peak standardized uptake value of ~2.0), [18F]OCM-50 was further evaluated in non-human primate and also showed good brain uptake and rapid clearance. Further studies to consider clinical translation of both radiotracers are underway.
Collapse
Affiliation(s)
- Cassis Varlow
- Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, M5T 1R8, Canada.,Institute of Medical Science, University of Toronto, Toronto, ON, M5T 1R8, Canada
| | - Andrew V Mossine
- Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109, United States
| | - Vadim Bernard-Gauthier
- Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, M5T 1R8, Canada
| | - Peter J H Scott
- Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109, United States
| | - Neil Vasdev
- Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, M5T 1R8, Canada.,Institute of Medical Science, University of Toronto, Toronto, ON, M5T 1R8, Canada
| |
Collapse
|
3
|
Hill J, Shao X, Wright JS, Stauff J, Sherman PS, Arteaga J, Wong KK, Viglianti BL, Scott PJH, Brooks AF. Synthesis and Evaluation of 11C- and 18F-Labeled SOAT1 Inhibitors as Macrophage Foam Cell Imaging Agents. ACS Med Chem Lett 2020; 11:1299-1304. [PMID: 32551015 PMCID: PMC7294710 DOI: 10.1021/acsmedchemlett.0c00127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Accepted: 04/30/2020] [Indexed: 11/30/2022] Open
Abstract
PD-132301, an inhibitor of sterol O-acyltransferase 1 (SOAT1; also known as acyl-coenzyme A:cholesterol acyltransferase-1, ACAT1), is under clinical investigation for numerous adrenal disorders. Radiolabeled SOAT1 inhibitors could support drug discovery and help diagnose SOAT1-related disorders, such as atherosclerosis. We synthesized two radiolabeled SOAT1 inhibitors, [11C]PD-132301 and fluorine analogue [18F]1. Rat biodistribution studies were conducted with both agents and, as the most selective tracer, [11C]PD-132301 was advanced to preclinical positron emission tomography studies in (atherosclerotic) ApoE-/- mice. The uptake of [11C]PD-132301 in SOAT1-rich tissue warrants further investigation into the compound as an atherosclerosis and adrenal imaging agent.
Collapse
Affiliation(s)
- James
R. Hill
- Institute
for Molecular Bioscience, The University
of Queensland, Brisbane, Queensland 4072, Australia
- Department
of Radiology, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Xia Shao
- Department
of Radiology, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Jay S. Wright
- Department
of Radiology, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Jenelle Stauff
- Department
of Radiology, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Phillip S. Sherman
- Department
of Radiology, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Janna Arteaga
- Department
of Radiology, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Ka Kit Wong
- Department
of Radiology, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Benjamin L. Viglianti
- Department
of Radiology, University of Michigan, Ann Arbor, Michigan 48109, United States
- Nuclear
Medicine Service, Veterans Administration, Ann Arbor, Michigan 48105, United States
| | - Peter J. H. Scott
- Department
of Radiology, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Allen F. Brooks
- Department
of Radiology, University of Michigan, Ann Arbor, Michigan 48109, United States
| |
Collapse
|
4
|
Bailey JJ, Kaiser L, Lindner S, Wüst M, Thiel A, Soucy JP, Rosa-Neto P, Scott PJH, Unterrainer M, Kaplan DR, Wängler C, Wängler B, Bartenstein P, Bernard-Gauthier V, Schirrmacher R. First-in-Human Brain Imaging of [ 18F]TRACK, a PET tracer for Tropomyosin Receptor Kinases. ACS Chem Neurosci 2019; 10:2697-2702. [PMID: 31017386 DOI: 10.1021/acschemneuro.9b00144] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
The tropomyosin receptor kinase TrkA/B/C family is responsible for human neuronal growth, survival, and differentiation from early nervous system development stages onward. Downregulation of TrkA/B/C receptors characterizes numerous neurological disorders including Alzheimer's disease (AD). Abnormally expressed Trk receptors or chimeric Trk fusion proteins are also well-characterized oncogenic drivers in a variety of neurogenic and non-neurogenic human neoplasms and are currently the focus of intensive clinical research. Previously, we have described the clinical translation of a highly selective and potent carbon-11-labeled pan-Trk radioligand and the preclinical characterization of the optimized fluorine-18-labeled analogue, [18F]TRACK, for in vivo Trk positron emission tomography (PET) imaging. We describe herein central nervous system selectivity assessment and first-in-human study of [18F]TRACK.
Collapse
Affiliation(s)
- Justin J. Bailey
- Department of Oncology, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - Lena Kaiser
- Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich 81377, Germany
| | - Simon Lindner
- Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich 81377, Germany
| | - Melinda Wüst
- Department of Oncology, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - Alexander Thiel
- McConnel Brain Imaging Centre, Montreal Neurological Institute, McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada
- Jewish General Hospital, Lady Davis Institute, Montreal, Quebec HT3 1E2, Canada
| | - Jean-Paul Soucy
- McConnel Brain Imaging Centre, Montreal Neurological Institute, McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada
| | - Pedro Rosa-Neto
- Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, Douglas Mental Health University Institute, Montreal, Quebec H4H 1R3, Canada
| | - Peter J. H. Scott
- Division of Nuclear Medicine, Department of Radiology, The University of Michigan Medical School, Ann Arbor, Michigan 48109, United States
| | - Marcus Unterrainer
- Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich 81377, Germany
| | - David R. Kaplan
- Program in Neurosciences and Mental Health, Hospital for Sick Children, Toronto, Ontario M5G 0A4, Canada
| | - Carmen Wängler
- Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, 68167 Mannheim, Germany
| | - Björn Wängler
- Molecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim 68167, Germany
| | - Peter Bartenstein
- Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich 81377, Germany
| | | | - Ralf Schirrmacher
- Department of Oncology, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| |
Collapse
|